Osteoporosis: New treatments and updates

Bulletin of the NYU Hospital for Joint Diseases

Volumn 69, Issue 3, 2011, Pages 253-256

  Honig, Stephen ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMG 785; CATHEPSIN K INHIBITOR; DENOSUMAB; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MONOCLONAL ANTIBODY; ODANACATIB; ONO 5334; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; SCLEROSTIN; UNCLASSIFIED DRUG;

ARTICLE; BONE MINERALIZATION; DRUG DOSE COMPARISON; ECZEMA; FEASIBILITY STUDY; FEMUR SUBTROCHANTERIC FRACTURE; HUMAN; INFECTION; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RASH; URINARY TRACT INFECTION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 80054110436     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
2. Bone HG, Chapurlat R, Drandi ML, et al. Denosumab treatment for 5 years of postmenopausal women with osteoporosis: results from the first two years of the FREDDOM trial extension. American Association of Clinical Endocrinologists Annual Meeting 2011, Abstract #503.
3. Reid IR, Miller PD, Brown JP. Effects on denosumab on bone histomorphometry: The FREEDOM and STAND studies. J Bone Min Res. 2010;25:2256-65.
4. Bone HG, McClung MR, Roux C, et al. Odanacatib, a Figure 1 Stress fracture of lateral femur (arrow) in women with long term alendronate use.cathepsin-k inhibitor for osteoporosis: a two year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25:937-47.
5. Heisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. J Bone Miner Res. 2011;26:242-51.
6. East ell R, Nagase S, Obama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The Ocean Study. J Bone Miner Res. 2011;6:1303-12.
7. Van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP simulated bone formation. J Bone Miner Res. 2007:22:19-28.
8. Poole KE, van Bezooijen RL, Love ridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842-4.
9. Minsk MS, Chatoyant L, Xuedong L, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of no fractured bones. J Bone Miner Res. 2011;26:1012-21.
10. Pasha D, Jang G, Slouch B, et al. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
11. Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation and communication: a role for nitric oxide. J Cell Biochem. 1995;57:339-408.
12. Jamal SA, Browner WS, Bauer DC, et al. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998;13:1755-9.
13. Wimakawansa SJ, Chapa MT, Yallampalli C, et al. Prevention of corticosteroid induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone. 1997;21:275-80.
14. Wimalawansa SJ, De Marco G, Fangula P, et al. Nitric oxide donor alleviated ovariectomy-induced bone loss. Bone. 1996;18:301-4.
15. Jamal SA, Goltzman D, Hanley DA. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009;20:737-44.
16. Jamal SA, Hamilton CJ, Eastell R, et al. Effect of nitroglycerin ointment on bone density and bone strength in postmenopausal women. JAMA. 2011;305:800-7.
17. Yadav VK, Je-Hwang R, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum: an entero-bone endocrine axis. Cell. 2008;135:825-37.
18. Yadav VJ, Balaji S, Suresh PS, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16:308-12.
19. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res. 2011;26: 533-60.
20. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349-53.
21. Odvina CV, Zerwekh JE, Rao DS. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-301.
22. Park-Wylie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783-9.
23. Schilcher J, Michaelson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728-37.